BRISBANE, Australia, Aug. 12, 2021 /PRNewswire/ -- Treatment with diabetes drug canagliflozin lowers the PromarkerD risk score for developing diabetic kidney disease in patients with type 2 diabetes, latest research suggests.
In a study presented at the Australasian Diabetes Congress today, researchers used PromarkerD, the world's
The study found the average PromarkerD risk score of patients taking canagliflozin, an SGLT2-inhibitor diabetes drug, reduced significantly during the three-year trial.
PromarkerD is a simple biomarker-based blood test developed by Australian medical technology company Proteomics International Laboratories Ltd (ASX:PIQ). It is the only available test capable of reliably predicting future kidney function decline in patients with type 2 diabetes and no existing DKD[*]. The PromarkerD prognostic test can predict the onset of the asymptomatic disease up to four years in advance.
Canagliflozin is an approved diabetes therapy with additional renal and cardiovascular benefits. It is the first diabetes medicine approved by the US Food and Drug Administration (FDA) to treat DKD, and shown to slow the disease progression in patients with type 2 diabetes and DKD.
The study examined the association between canagliflozin and change in PromarkerD risk scores over a three-year period in type 2 diabetes patients in the completed CANagliflozin cardioVascular Assessment Study (CANVAS). The research retrospectively measured PromarkerD risk scores for developing DKD in blood samples from 2,008 patients taken at the start of the trial and again three years later. All patients had diabetes but no existing DKD, and were randomly allocated to take either canagliflozin or a placebo.
The study found the average PromarkerD risk score in patients taking canagliflozin dropped 1% during the trial, while the average risk score of patients taking a placebo rose 4%[†]. Importantly, the greatest reductions in risk score were seen in the patients classified by PromarkerD as being at high risk of developing DKD at the start of the trial - here the PromarkerD risk score of patients taking canagliflozin dropped 6%. Each of these results was statistically significant.
Proteomics International managing director Dr Richard Lipscombe said the research further validated the power of the PromarkerD test. "Our previously published clinical studies have shown the power of PromarkerD to predict the onset of diabetic kidney disease before clinical symptoms appear," he said.
"Now, for the first time, we are confirming that this SGLT2 inhibitor class of diabetes drug can improve people's renal risk profile. It means there is a potential treatment for type 2 diabetes patients identified by PromarkerD as being at high risk of diabetic kidney disease, giving them the chance to reduce their risk of developing symptoms in the future."
The study is being presented at the Australasian Diabetes Congress in Brisbane, from 11-13 August 2021.
About PromarkerD (www.PromarkerD.com)Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique 'fingerprint' of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR))]. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years. The PromarkerD test is CE Mark registered in the European Union.
Further information is available through the PromarkerD web portal.
To view the presentation or visit the PromarkerD virtual booth please see: www.PromarkerD.com/product
About Proteomics International Laboratories (PILL) See www.proteomicsinternational.com
